| ［1］ |
Barot SV, Sangwan N, Nair KG, et al. Distinct intratumoral microbiome of young-onset and average-onset colorectal cancer[J]. EBioMedicine, 2024, 100: 104980.
|
| ［2］ |
Bai X, Wei H, Liu W, et al. Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites[J]. Gut, 2022, 71(12): 2439–2450.
|
| ［3］ |
Hu M, Xu Y, Wang Y, et al. Gut microbial-derived N-acetylmuramic acid alleviates colorectal cancer via the AKT1 pathway[J]. Gut, 2025: gutjnl-2024–332891.
|
| ［4］ |
Huang J, Lucero-Prisno DE, 3rd, Zhang L, et al. Updated epidemiology of gastrointestinal cancers in East Asia[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(5): 271–287.
|
| ［5］ |
Li Y, Liu Z, Yan H, et al. Polygonatum sibiricum polysaccharide ameliorates skeletal muscle aging and mitochondrial dysfunction via PI3K/Akt/mTOR signaling pathway[J]. Phytomedicine, 2025, 136: 156316.
|
| ［6］ |
Li X, Jiang Z, Li J, et al. PRELP inhibits colorectal cancer progression by suppressing epithelial-mesenchymal transition and angiogenesis via the inactivation of the FGF1/PI3K/AKT pathway[J]. Apoptosis, 2025, 30(1–2): 16–34.
|
| ［7］ |
Griffioen AW, Nowak-Sliwinska P. A cellular danse macabre: the choreography of programmed cell death[J]. Apoptosis, 2025, 30(3–4): 507–511.
|
| ［8］ |
Wang C, You Z, Zhou G, et al. Amarogentin suppresses cell proliferation and EMT process through inducing ferroptosis in colorectal cancer[J]. BMC Gastroenterol, 2025, 25(1): 46.
|
| ［9］ |
Tian LY, Smit DJ, Popova NV, et al. All three AKT isoforms can upregulate oxygen metabolism and lactate production in human hepatocellular carcinoma cell lines[J]. Int J Mol Sci, 2024, 25(4): 2168.
|
| ［10］ |
Liu Y, Zhang M, Jang H, et al. The allosteric mechanism of mTOR activation can inform bitopic inhibitor optimization[J]. Chem Sci, 2024, 15(3): 1003–1017.
|
| ［11］ |
Hsiao KC, Ruan SY, Chen SM, et al. The B56γ3-containing protein phosphatase 2A attenuates p70S6K-mediated negative feedback loop to enhance AKT-facilitated epithelial-mesenchymal transition in colorectal cancer[J]. Cell Commun Signal, 2023, 21(1): 172.
|
| ［12］ |
Wang G, Feng CC, Chu SJ, et al. Toosendanin inhibits growth and induces apoptosis in colorectal cancer cells through suppression of AKT/GSK-3β/β-catenin pathway[J]. Int J Oncol, 2015, 47(5): 1767–1774.
|
| ［13］ |
Gao Q, Li L, Zhang QM, et al. Monotropein induced apoptosis and suppressed cell cycle progression in colorectal cancer cells[J]. Chin J Integr Med, 2024, 30(1): 25–33.
|
| ［14］ |
Wang H, Chen Y, Yuan Q, et al. HRK inhibits colorectal cancer cells proliferation by suppressing the PI3K/AKT/mTOR pathway[J]. Front Oncol, 2022, 12: 1053510.
|
| ［15］ |
Wu M, Li R, Qin J, et al. ERO1α promotes the proliferation and inhibits apoptosis of colorectal cancer cells by regulating the PI3K/AKT pathway[J]. J Mol Histol, 2023, 54(6): 621–631.
|
| ［16］ |
Han H, Wen Z, Yang M, et al. Shikonin derivative suppresses colorectal cancer cells growth via reactive pxygen species-mediated mitochondrial apoptosis and PI3K/AKT pathway[J]. Chem Biodivers, 2025: e202403291.
|
| ［17］ |
Niu X, You Q, Hou K, et al. Autophagy in cancer development, immune evasion, and drug resistance[J]. Drug Resist Updat, 2025, 78: 101170.
|
| ［18］ |
Zhou X, Zhao Y, Huang S, et al. TRIM32 promotes neuronal ferroptosis by enhancing K63-linked ubiquitination and subsequent p62-selective autophagic degradation of GPX4[J]. Int J Biol Sci, 2025, 21(3): 1259–1274.
|
| ［19］ |
Li F, Wan X, Li Z, et al. High glucose inhibits autophagy and promotes the proliferation and metastasis of colorectal cancer through the PI3K/AKT/mTOR pathway[J]. Cancer Med, 2024, 13(11): e7382.
|
| ［20］ |
Li Z, Ke H, Cai J, et al. MTHFD1 regulates autophagy to promote growth and metastasis in colorectal cancer via the PI3K-AKT-mTOR signaling pathway[J]. Cancer Med, 2024, 13(22): e70267.
|
| ［21］ |
Hao J, Mei H, Luo Q, et al. TCL1A acts as a tumour suppressor by modulating gastric cancer autophagy via miR-181a-5p-TCL1A-Akt/mTOR-c-MYC loop[J]. Carcinogenesis, 2023, 44(1): 29–37.
|
| ［22］ |
Yang C, Yaolin S, Lu W, et al. G-protein signaling modulator 1 promotes colorectal cancer metastasis by PI3K/AKT/mTOR signaling and autophagy[J]. Int J Biochem Cell Biol, 2023, 157: 106388.
|
| ［23］ |
Yang Y, Chen H, Huang S, et al. BOK-engaged mitophagy alleviates neuropathology in Alzheimer’s disease[J]. Brain, 2025, 148(2): 432–447.
|
| ［24］ |
Iskandar K, Foo J, Liew AQX, et al. A novel MTORC2-AKT-ROS axis triggers mitofission and mitophagy-associated execution of colorectal cancer cells upon drug-induced activation of mutant KRAS[J]. Autophagy, 2024, 20(6): 1418–1441.
|
| ［25］ |
Du S, Zeng F, Sun H, et al. Prognostic and therapeutic significance of a novel ferroptosis related signature in colorectal cancer patients[J]. Bioengineered, 2022, 13(2): 2498–2512.
|
| ［26］ |
Li J, Jiang JL, Chen YM, et al. KLF2 inhibits colorectal cancer progression and metastasis by inducing ferroptosis via the PI3K/AKT signaling pathway[J]. J Pathol Clin Res, 2023, 9(5): 423–435.
|
| ［27］ |
Liu L, Zhang C, Yang B, et al. MARCH8 ubiquitinates and degrades CEMIP to induce colorectal cancer cell ferroptosis through inactivating PI3K/AKT pathway[J]. Pathol Res Pract, 2025, 269: 155909.
|
| ［28］ |
Aziguli T, Xiao SY, Yang Y, et al. ENO1 promotes PDAC progression by inhibiting CD8(+) T cell infiltration through upregulating PD-L1 expression via HIF-1α signaling[J]. Transl Oncol, 2025, 52: 102261.
|
| ［29］ |
Hu X, Liu J, Wang Q, et al. Colon cancer-cell-specific drug delivery by gemcitabine conjugated with peptide chain targeting ENO1[J]. Int J Pharm, 2025, 673: 125402.
|
| ［30］ |
Liu Y, Hou Y, Zhang F, et al. ENO1 deletion potentiates ferroptosis and decreases glycolysis in colorectal cancer cells via AKT/STAT3 signaling[J]. Exp Ther Med, 2024, 27(4): 127.
|
| ［31］ |
Jin H, Zhu M, Zhang D, et al. B7H3 increases ferroptosis resistance by inhibiting cholesterol metabolism in colorectal cancer[J]. Cancer Sci, 2023, 114(11): 4225–4236.
|
| ［32］ |
Zhao MM, Ren TT, Wang JK, et al. Endoplasmic reticulum membrane remodeling by targeting reticulon-4 induces pyroptosis to facilitate antitumor immune[J]. Protein Cell, 2025, 16(2): 121–135.
|
| ［33］ |
Li L, Zhao L, Zhou D, et al. Targeting pyroptosis reverses KIAA1199-mediated immunotherapy resistance in colorectal cancer[J]. J Immunother Cancer, 2025, 13(2): e010000.
|
| ［34］ |
Han W, Xing W, Wang K, et al. Alisol A attenuates malignant phenotypes of colorectal cancer cells by inactivating PI3K/Akt signaling[J]. Oncol Lett, 2022, 24(2): 249.
|
| ［35］ |
Chen T, Wang Z, Zhong J, et al. Secoisolariciresinol diglucoside induces pyroptosis by activating caspase-1 to cleave GSDMD in colorectal cancer cells[J]. Drug Dev Res, 2022, 83(5): 1152–1166.
|
| ［36］ |
Liu WQ, Lin WR, Yan L, et al. Copper homeostasis and cuproptosis in cancer immunity and therapy[J]. Immunol Rev, 2024, 321(1): 211–227.
|
| ［37］ |
Zhang Q, Ma L, Zhou H, et al. A prognostic signature of cuproptosis and TCA-related genes for hepatocellular carcinoma[J]. Front Oncol, 2022, 12: 1040736.
|
| ［38］ |
Huang T, Zhang Y, Wu Y, et al. CEBPB dampens the cuproptosis sensitivity of colorectal cancer cells by facilitating the PI3K/AKT/mTOR signaling pathway[J]. Saudi J Gastroenterol, 2024, 30(6): 381–388.
|
| ［39］ |
Yang S, Zhu Z, Zhang X, et al. Idelalisib induces PUMA-dependent apoptosis in colon cancer cells[J]. Oncotarget, 2017, 8(4): 6102–6113.
|
| ［40］ |
Landry MR, Duross AN, Neufeld MJ, et al. Low dose novel PARP-PI3K inhibition via nanoformulation improves colorectal cancer immunoradiotherapy[J]. Mater Today Bio, 2020, 8: 100082.
|
| ［41］ |
Bukum N, Novotna E, Morell A, et al. Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3[J]. Chem Biol Interact, 2019, 302: 101–107.
|
| ［42］ |
El-Daly SM, Abo-Elfadl MT, Hussein J, et al. Enhancement of the antitumor effect of 5-fluorouracil with modulation in drug transporters expression using PI3K inhibitors in colorectal cancer cells[J]. Life Sci, 2023, 315: 121320.
|
| ［43］ |
Sun L, Huang Y, Liu Y, et al. Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis[J]. Cell Death Dis, 2018, 9(9): 911.
|
| ［44］ |
Ding X, Chen T, Shi Q, et al. INTS6 promotes colorectal cancer progression by activating of AKT and ERK signaling[J]. Exp Cell Res, 2021, 407(2): 112826.
|
| ［45］ |
Chen M, Tan AH, Li J. Curcumin represses colorectal cancer cell proliferation by triggering ferroptosis via PI3K/Akt/mTOR signaling[J]. Nutr Cancer, 2023, 75(2): 726–733.
|
| ［46］ |
Dai W, Dai YG, Ren DF, et al. Dieckol, a natural polyphenolic drug, inhibits the proliferation and migration of colon cancer cells by inhibiting PI3K, AKT, and mTOR phosphorylation[J]. J Biochem Mol Toxicol, 2023, 37(5): e23313.
|
| ［47］ |
Mu B X, Li Y, Ye N, et al. Understanding apoptotic induction by Sargentodoxa cuneata-Patrinia villosa herb pair via PI3K/AKT/mTOR signalling in colorectal cancer cells using network pharmacology and cellular studies[J]. J Ethnopharmacol, 2024, 319(Pt 3): 117342.
|
| ［48］ |
Liu Y, Zhu Y, Gu L, et al. Chloroquine suppresses colorectal cancer progression via targeting CHKA and PFKM to inhibit the PI3K/AKT pathway and the Warburg effect[J]. Int J Biol Sci, 2025, 21(4): 1619–1631.
|
| ［49］ |
Chu J, Yuan C, Zhou L, et al. JianPiTongLuo (JPTL) Recipe regulates anti-apoptosis and cell proliferation in colorectal cancer through the PI3K/AKT signaling pathway[J]. Heliyon, 2024, 10(15): e35490.
|
| ［50］ |
Zheng Q, Jing S, Hu L, et al. Evodiamine inhibits colorectal cancer growth via RTKs mediated PI3K/AKT/p53 signaling pathway[J]. J Cancer, 2024, 15(8): 2361–2372.
|